Dr. Slamon describes results of genomic seqncng to determine who benefits from adding
everolimus (an mTor inhibitor which ffeecets the PI3k pathway) to herceptin in Stage IV patients
http://meetinglibrary.asco.org/content/112020?media=vm |
Re: Dr. Slamon describes results of genomic seqncng to determine who benefits from ad
yes interesting and here's more on the subject:
http://www.ascopost.com/ViewNews.aspx?nid=20674 sarah |
All times are GMT -7. The time now is 06:55 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021